{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:23:39Z","timestamp":1789629819525,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00228-025-03825-7","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T22:45:15Z","timestamp":1742942715000},"page":"785-799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploring the comprehensive factors influencing tacrolimus pharmacokinetics in early renal transplant recipients: A population pharmacokinetic analysis"],"prefix":"10.1007","volume":"81","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linkun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"issue":"1","key":"3825_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2009.02.018","volume":"56","author":"RV Navarrete","year":"2009","unstructured":"Navarrete RV (2009) Renal transplantation with living-donor surgical strategies: a view with 40 years of experience. Eur Urol 56(1):38\u201339. https:\/\/doi.org\/10.1016\/j.eururo.2009.02.018","journal-title":"Eur Urol"},{"issue":"6","key":"3825_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJM199408113310606","volume":"331","author":"M Suthanthiran","year":"1994","unstructured":"Suthanthiran M, Strom TB (1994) Renal transplantation. N Engl J Med 331(6):365\u2013376. https:\/\/doi.org\/10.1056\/NEJM199408113310606","journal-title":"N Engl J Med"},{"issue":"6","key":"3825_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMe048335","volume":"352","author":"JR Ingelfinger","year":"2005","unstructured":"Ingelfinger JR (2005) Agonistic autoantibodies and rejection of renal allografts. N Engl J Med 352(6):617\u2013619. https:\/\/doi.org\/10.1056\/NEJMe048335","journal-title":"N Engl J Med"},{"issue":"1","key":"3825_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s13318-021-00735-8","volume":"47","author":"J Methaneethorn","year":"2022","unstructured":"Methaneethorn J, Lohitnavy M, Onlamai K, Leelakanok N (2022) Predictive performance of published tacrolimus population pharmacokinetic models in Thai kidney transplant patients. Eur J Drug Metab Pharmacokinet 47(1):105\u2013116. https:\/\/doi.org\/10.1007\/s13318-021-00735-8","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"10","key":"3825_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43(10):623\u2013653. https:\/\/doi.org\/10.2165\/00003088-200443100-00001","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"3825_CR6","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE (2020) Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Clin Pharmacokinet 59(11):1357\u20131392. https:\/\/doi.org\/10.1007\/s40262-020-00922-x","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"3825_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40262-024-01414-y","volume":"63","author":"Y Hoffert","year":"2024","unstructured":"Hoffert Y, Dia N, Vanuytsel T, Vos R, Kuypers D, Van Cleemput J, Verbeek J, Dreesen E (2024) Model-informed precision dosing of tacrolimus: a systematic review of population pharmacokinetic models and a benchmark study of software tools. Clin Pharmacokinet 63(10):1407\u20131421. https:\/\/doi.org\/10.1007\/s40262-024-01414-y","journal-title":"Clin Pharmacokinet"},{"key":"3825_CR8","doi-asserted-by":"publisher","unstructured":"Holford N, Ma G, Metz D (2022) TDM is dead. Long live TCI! Br J Clin Pharmacol 88 (4): 1406\u20131413 https:\/\/doi.org\/10.1111\/bcp.14434","DOI":"10.1111\/bcp.14434"},{"issue":"7","key":"3825_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00228-023-03503-6","volume":"79","author":"CB Wang","year":"2023","unstructured":"Wang CB, Zhang YJ, Zhao MM, Zhao LM (2023) Population pharmacokinetic analyses of tacrolimus in non-transplant patients: a systematic review. Eur J Clin Pharmacol 79(7):897\u2013913. https:\/\/doi.org\/10.1007\/s00228-023-03503-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3825_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.kint.2023.06.021","volume":"104","author":"N Lloberas","year":"2023","unstructured":"Lloberas N, Grinyo JM, Colom H, Vidal-Alabro A, Fontova P, Rigo-Bonnin R, Padro A, Bestard O, Melilli E, Montero N, Coloma A, Manonelles A, Meneghini M, Fava A, Torras J, Cruzado JM (2023) A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction. Kidney Int 104(4):840\u2013850. https:\/\/doi.org\/10.1016\/j.kint.2023.06.021","journal-title":"Kidney Int"},{"issue":"6","key":"3825_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1365-2125.2007.02895.x","volume":"64","author":"M Antignac","year":"2007","unstructured":"Antignac M, Barrou B, Farinotti R, Lechat P, Urien S (2007) Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 64(6):750\u2013757. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02895.x","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3825_CR12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bcp.12830","volume":"81","author":"CY Zhao","year":"2016","unstructured":"Zhao CY, Jiao Z, Mao JJ, Qiu XY (2016) External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol 81(5):891\u2013907. https:\/\/doi.org\/10.1111\/bcp.12830","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3825_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3343\/alm.2018.38.2.85","volume":"38","author":"X Qin","year":"2018","unstructured":"Qin X, Rui J, Xia Y, Mu H, Song SH, Raja Aziddin RE, Miles G, Sun Y, Chun S (2018) Multi-center performance evaluations of tacrolimus and cyclosporine electrochemiluminescence immunoassays in the Asia-Pacific Region. Ann Lab Med 38(2):85\u201394. https:\/\/doi.org\/10.3343\/alm.2018.38.2.85","journal-title":"Ann Lab Med"},{"issue":"5\u20136","key":"3825_CR14","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000331856","volume":"88","author":"L Xue","year":"2011","unstructured":"Xue L, Zhang H, Ma S, Rui JZ, Miao LY (2011) Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers. Pharmacology 88(5\u20136):288\u2013294. https:\/\/doi.org\/10.1159\/000331856","journal-title":"Pharmacology"},{"issue":"4","key":"3825_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/jcpt.12523","volume":"42","author":"HJ Zhang","year":"2017","unstructured":"Zhang HJ, Li DY, Zhu HJ, Fang Y, Liu TS (2017) Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. J Clin Pharm Ther 42(4):425\u2013432. https:\/\/doi.org\/10.1111\/jcpt.12523","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"3825_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/jcpt.12396","volume":"41","author":"S Vadcharavivad","year":"2016","unstructured":"Vadcharavivad S, Praisuwan S, Techawathanawanna N, Treyaprasert W, Avihingsanon Y (2016) Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. J Clin Pharm Ther 41(3):310\u2013328. https:\/\/doi.org\/10.1111\/jcpt.12396","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"3825_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/bcpt.12176","volume":"114","author":"N Han","year":"2014","unstructured":"Han N, Ha S, Yun HY, Kim MG, Min SI, Ha J, Lee JI, Oh JM, Kim IW (2014) Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol Toxicol 114(5):400\u2013406. https:\/\/doi.org\/10.1111\/bcpt.12176","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3825_CR18","doi-asserted-by":"publisher","unstructured":"Ansermot N, Fathi M, Veuthey JL, Desmeules J, Rudaz S, Hochstrasser D (2008) Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique. Clin Biochem 41 (10\u201311): 910\u2013913 https:\/\/doi.org\/10.1016\/j.clinbiochem.2008.02.015","DOI":"10.1016\/j.clinbiochem.2008.02.015"},{"key":"3825_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.plabm.2017.03.001","volume":"8","author":"M Sasano","year":"2017","unstructured":"Sasano M, Kimura S, Maeda I, Hidaka Y (2017) Analytical performance evaluation of the Elecsys(R) Cyclosporine and Elecsys(R) Tacrolimus assays on the cobas e411 analyzer. Pract Lab Med 8:10\u201317. https:\/\/doi.org\/10.1016\/j.plabm.2017.03.001","journal-title":"Pract Lab Med"},{"issue":"1","key":"3825_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","volume":"70","author":"E Storset","year":"2014","unstructured":"Storset E, Holford N, Midtvedt K, Bremer S, Bergan S, Asberg A (2014) Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol 70(1):65\u201377. https:\/\/doi.org\/10.1007\/s00228-013-1584-7","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3825_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29(6):404\u2013430. https:\/\/doi.org\/10.2165\/00003088-199529060-00003","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3825_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1046\/j.1365-2125.2000.00288.x","volume":"50","author":"WJ Sam","year":"2000","unstructured":"Sam WJ, Aw M, Quak SH, Lim SM, Charles BG, Chan SY, Ho PC (2000) Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 50(6):531\u2013541. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00288.x","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"3825_CR23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/sj.bmt.1703224","volume":"28","author":"P Jacobson","year":"2001","unstructured":"Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC (2001) Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant 28(8):753\u2013758. https:\/\/doi.org\/10.1038\/sj.bmt.1703224","journal-title":"Bone Marrow Transplant"},{"issue":"6\u20137","key":"3825_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s002280100331","volume":"57","author":"S Fukatsu","year":"2001","unstructured":"Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K, Tanaka K, Inui K (2001) Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 57(6\u20137):479\u2013484. https:\/\/doi.org\/10.1007\/s002280100331","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3825_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/FTD.0b013e3181aab02b","volume":"31","author":"JE Wallin","year":"2009","unstructured":"Wallin JE, Friberg LE, Fasth A, Staatz CE (2009) Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Monit 31(4):457\u2013466. https:\/\/doi.org\/10.1097\/FTD.0b013e3181aab02b","journal-title":"Ther Drug Monit"},{"issue":"1","key":"3825_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11095-019-2740-2","volume":"37","author":"L Xue","year":"2019","unstructured":"Xue L, Zhang WJ, Tian JX, Liu LN, Yan HH, Zhang WW, Ding XL, Zhang JJ, Miao LY (2019) Multicenter-based population pharmacokinetic analysis of ciclosporin in hematopoietic stem cell transplantation patients. Pharm Res 37(1):15. https:\/\/doi.org\/10.1007\/s11095-019-2740-2","journal-title":"Pharm Res"},{"issue":"5","key":"3825_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1211\/jpp\/61.05.0002","volume":"61","author":"K Thelen","year":"2009","unstructured":"Thelen K, Dressman JB (2009) Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 61(5):541\u2013558. https:\/\/doi.org\/10.1211\/jpp\/61.05.0002","journal-title":"J Pharm Pharmacol"},{"issue":"8781","key":"3825_CR28","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-i","volume":"338","author":"JC Kolars","year":"1991","unstructured":"Kolars JC, Awni WM, Merion RM, Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338(8781):1488\u20131490. https:\/\/doi.org\/10.1016\/0140-6736(91)92302-i","journal-title":"Lancet"},{"issue":"1","key":"3825_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0009-9236(97)90150-8","volume":"62","author":"LC Floren","year":"1997","unstructured":"Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62(1):41\u201349. https:\/\/doi.org\/10.1016\/S0009-9236(97)90150-8","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"3825_CR30","doi-asserted-by":"publisher","first-page":"728","DOI":"10.5414\/CP202152","volume":"53","author":"JJ Zhang","year":"2015","unstructured":"Zhang JJ, Liu SB, Xue L, Ding XL, Zhang H, Miao LY (2015) The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther 53(9):728\u2013736. https:\/\/doi.org\/10.5414\/CP202152","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3825_CR31","doi-asserted-by":"publisher","unstructured":"Zhang F, He F, Li L, Guo L, Zhang B, Yu S, Zhao W (2020) Bioavailability based on the gut microbiota: a new perspective. Microbiol Mol Biol Rev 84 (2) https:\/\/doi.org\/10.1128\/MMBR.00072-19","DOI":"10.1128\/MMBR.00072-19"},{"issue":"7877","key":"3825_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41586-021-03891-8","volume":"597","author":"M Klunemann","year":"2021","unstructured":"Klunemann M, Andrejev S, Blasche S, Mateus A, Phapale P, Devendran S, Vappiani J, Simon B, Scott TA, Kafkia E, Konstantinidis D, Zirngibl K, Mastrorilli E, Banzhaf M, Mackmull MT, Hovelmann F, Nesme L, Brochado AR, Maier L, Bock T, Periwal V, Kumar M, Kim Y, Tramontano M, Schultz C, Beck M, Hennig J, Zimmermann M, Sevin DC, Cabreiro F, Savitski MM, Bork P, Typas A, Patil KR (2021) Bioaccumulation of therapeutic drugs by human gut bacteria. Nature 597(7877):533\u2013538. https:\/\/doi.org\/10.1038\/s41586-021-03891-8","journal-title":"Nature"},{"issue":"3","key":"3825_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1124\/dmd.118.084772","volume":"47","author":"Y Guo","year":"2019","unstructured":"Guo Y, Crnkovic CM, Won KJ, Yang X, Lee JR, Orjala J, Lee H, Jeong H (2019) Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites. Drug Metab Dispos 47(3):194\u2013202. https:\/\/doi.org\/10.1124\/dmd.118.084772","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"3825_CR34","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ajt.12588","volume":"14","author":"WF Fricke","year":"2014","unstructured":"Fricke WF, Maddox C, Song Y, Bromberg JS (2014) Human microbiota characterization in the course of renal transplantation. Am J Transplant 14(2):416\u2013427. https:\/\/doi.org\/10.1111\/ajt.12588","journal-title":"Am J Transplant"},{"issue":"7","key":"3825_CR35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/TP.0000000000000370","volume":"98","author":"JR Lee","year":"2014","unstructured":"Lee JR, Muthukumar T, Dadhania D, Toussaint NC, Ling L, Pamer E, Suthanthiran M (2014) Gut microbial community structure and complications after kidney transplantation: a pilot study. Transplantation 98(7):697\u2013705. https:\/\/doi.org\/10.1097\/TP.0000000000000370","journal-title":"Transplantation"},{"issue":"6","key":"3825_CR36","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1067\/mcp.2002.129304","volume":"72","author":"CE Staatz","year":"2002","unstructured":"Staatz CE, Willis C, Taylor PJ, Tett SE (2002) Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 72(6):660\u2013669. https:\/\/doi.org\/10.1067\/mcp.2002.129304","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3825_CR37","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/j.1365-2125.2011.04039.x","volume":"72","author":"C Passey","year":"2011","unstructured":"Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA (2011) Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 72(6):948\u2013957. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04039.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3825_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00228-012-1296-4","volume":"69","author":"N Han","year":"2013","unstructured":"Han N, Yun HY, Hong JY, Kim IW, Ji E, Hong SH, Kim YS, Ha J, Shin WG, Oh JM (2013) Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol 69(1):53\u201363. https:\/\/doi.org\/10.1007\/s00228-012-1296-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3825_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/FTD.0b013e31829f1ab8","volume":"36","author":"TK Bergmann","year":"2014","unstructured":"Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE (2014) Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit 36(1):62\u201370. https:\/\/doi.org\/10.1097\/FTD.0b013e31829f1ab8","journal-title":"Ther Drug Monit"},{"key":"3825_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejps.2013.10.008","volume":"52","author":"B Golubovic","year":"2014","unstructured":"Golubovic B, Vucicevic K, Radivojevic D, Kovacevic SV, Prostran M, Miljkovic B (2014) Total plasma protein effect on tacrolimus elimination in kidney transplant patients\u2013population pharmacokinetic approach. Eur J Pharm Sci 52:34\u201340. https:\/\/doi.org\/10.1016\/j.ejps.2013.10.008","journal-title":"Eur J Pharm Sci"},{"issue":"13","key":"3825_CR41","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/pgs-2017-0139","volume":"19","author":"W Zhu","year":"2018","unstructured":"Zhu W, Xue L, Peng H, Duan Z, Zheng X, Cao D, Wen J, Wei X (2018) Tacrolimus population pharmacokinetic models according to CYP3A5\/CYP3A4\/POR genotypes in Chinese Han renal transplant patients. Pharmacogenomics 19(13):1013\u20131025. https:\/\/doi.org\/10.2217\/pgs-2017-0139","journal-title":"Pharmacogenomics"},{"issue":"13","key":"3825_CR42","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2165\/00003088-200342130-00006","volume":"42","author":"M Fukudo","year":"2003","unstructured":"Fukudo M, Yano I, Fukatsu S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K (2003) Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet 42(13):1161\u20131178. https:\/\/doi.org\/10.2165\/00003088-200342130-00006","journal-title":"Clin Pharmacokinet"},{"key":"3825_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/713650","volume":"2014","author":"L Zhu","year":"2014","unstructured":"Zhu L, Wang H, Sun X, Rao W, Qu W, Zhang Y, Sun L (2014) The population pharmacokinetic models of tacrolimus in Chinese adult liver transplantation patients. J Pharm (Cairo) 2014:713650. https:\/\/doi.org\/10.1155\/2014\/713650","journal-title":"J Pharm (Cairo)"},{"key":"3825_CR44","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2147\/TCRM.S184376","volume":"14","author":"E Ji","year":"2018","unstructured":"Ji E, Kim MG, Oh JM (2018) CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. Ther Clin Risk Manag 14:2119\u20132126. https:\/\/doi.org\/10.2147\/TCRM.S184376","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"3825_CR45","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jcpt.12599","volume":"42","author":"B Chen","year":"2017","unstructured":"Chen B, Shi HQ, Liu XX, Zhang WX, Lu JQ, Xu BM, Chen H (2017) Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther 42(6):679\u2013688. https:\/\/doi.org\/10.1111\/jcpt.12599","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"3825_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13318-017-0425-y","volume":"43","author":"XF Guan","year":"2018","unstructured":"Guan XF, Li DY, Yin WJ, Ding JJ, Zhou LY, Wang JL, Ma RR, Zuo XC (2018) Population pharmacokinetic modeling of diltiazem in Chinese renal transplant recipients. Eur J Drug Metab Pharmacokinet 43(1):55\u201362. https:\/\/doi.org\/10.1007\/s13318-017-0425-y","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3825_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107827","volume":"98","author":"L Li","year":"2021","unstructured":"Li L, Zhu M, Li DY, Guo HL, Hu YH, Xu ZY, Jing X, Chen F, Zhao F, Li YM, Xu J, Jiao Z (2021) Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. Int Immunopharmacol 98:107827. https:\/\/doi.org\/10.1016\/j.intimp.2021.107827","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"3825_CR48","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/tpj.2010.42","volume":"11","author":"JL Li","year":"2011","unstructured":"Li JL, Wang XD, Chen SY, Liu LS, Fu Q, Chen X, Teng LC, Wang CX, Huang M (2011) Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics J 11(4):300\u2013306. https:\/\/doi.org\/10.1038\/tpj.2010.42","journal-title":"Pharmacogenomics J"},{"key":"3825_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.110906","volume":"391","author":"S Huang","year":"2024","unstructured":"Huang S, Song W, Jiang S, Li Y, Wang M, Yang N, Zhu H (2024) Pharmacokinetic interactions between tacrolimus and Wuzhi capsule in liver transplant recipients: genetic polymorphisms affect the drug interaction. Chem Biol Interact 391:110906. https:\/\/doi.org\/10.1016\/j.cbi.2024.110906","journal-title":"Chem Biol Interact"},{"issue":"3","key":"3825_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bcpt.12914","volume":"122","author":"H Zhang","year":"2018","unstructured":"Zhang H, Bu F, Li L, Jiao Z, Ma G, Cai W, Zhuang X, Lin HS, Shin JG, Xiang X (2018) Prediction of drug-drug interaction between tacrolimus and principal ingredients of Wuzhi capsule in Chinese healthy volunteers using physiologically-based pharmacokinetic modelling. Basic Clin Pharmacol Toxicol 122(3):331\u2013340. https:\/\/doi.org\/10.1111\/bcpt.12914","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3825_CR51","doi-asserted-by":"publisher","unstructured":"He Q, Bu F, Zhang H, Wang Q, Tang Z, Yuan J, Lin HS, Xiang X (2021) Investigation of the Impact of CYP3A5 Polymorphism on drug-drug interaction between tacrolimus and Schisantherin A\/Schisandrin A based on physiologically-based pharmacokinetic modeling. Pharmaceuticals (Basel) 14 (3) https:\/\/doi.org\/10.3390\/ph14030198","DOI":"10.3390\/ph14030198"},{"issue":"2","key":"3825_CR52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/bdd.2311","volume":"43","author":"F Teng","year":"2022","unstructured":"Teng F, Zhang W, Wang W, Chen J, Liu S, Li M, Li L, Guo W, Wei H (2022) Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Biopharm Drug Dispos 43(2):76\u201385. https:\/\/doi.org\/10.1002\/bdd.2311","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"3825_CR53","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/00498254.2022.2073851","volume":"52","author":"Y Du","year":"2022","unstructured":"Du Y, Song W, Xiong X, Ge W, Zhu H (2022) Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients. Xenobiotica 52(3):274\u2013283. https:\/\/doi.org\/10.1080\/00498254.2022.2073851","journal-title":"Xenobiotica"},{"issue":"4","key":"3825_CR54","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/jcpt.12828","volume":"44","author":"DD Wang","year":"2019","unstructured":"Wang DD, Chen X, Li ZP (2019) Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: a retrospective study. J Clin Pharm Ther 44(4):611\u2013617. https:\/\/doi.org\/10.1111\/jcpt.12828","journal-title":"J Clin Pharm Ther"},{"key":"3825_CR55","doi-asserted-by":"publisher","first-page":"1352323","DOI":"10.3389\/fphar.2024.1352323","volume":"15","author":"M Miedziaszczyk","year":"2024","unstructured":"Miedziaszczyk M, Karczewski M, Grabowski T, Wolc A, Idasiak-Piechocka I (2024) Assessment of omeprazole and famotidine effects on the pharmacokinetics of tacrolimus in patients following kidney transplant-randomized controlled trial. Front Pharmacol 15:1352323. https:\/\/doi.org\/10.3389\/fphar.2024.1352323","journal-title":"Front Pharmacol"},{"key":"3825_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115149","volume":"166","author":"M Miedziaszczyk","year":"2023","unstructured":"Miedziaszczyk M, Idasiak-Piechocka I (2023) Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients - a review. Biomed Pharmacother 166:115149. https:\/\/doi.org\/10.1016\/j.biopha.2023.115149","journal-title":"Biomed Pharmacother"},{"key":"3825_CR57","doi-asserted-by":"publisher","unstructured":"Concha J, Sanguesa E, Saez-Benito AM, Aznar I, Berenguer N, Saez-Benito L, Ribate MP, Garcia CB (2023) Importance of pharmacogenetics and drug-drug interactions in a kidney transplanted patient. Life (Basel) 13 (8) https:\/\/doi.org\/10.3390\/life13081627","DOI":"10.3390\/life13081627"},{"issue":"4","key":"3825_CR58","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/dmd.108.025833","volume":"37","author":"K Hosohata","year":"2009","unstructured":"Hosohata K, Masuda S, Katsura T, Takada Y, Kaido T, Ogura Y, Oike F, Egawa H, Uemoto S, Inui K (2009) Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos 37(4):821\u2013826. https:\/\/doi.org\/10.1124\/dmd.108.025833","journal-title":"Drug Metab Dispos"},{"issue":"Pt A","key":"3825_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110866","volume":"124","author":"CB Wang","year":"2023","unstructured":"Wang CB, Zhang YJ, Zhao MM, Zhao L (2023) Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus. Int Immunopharmacol 124(Pt A):110866. https:\/\/doi.org\/10.1016\/j.intimp.2023.110866","journal-title":"Int Immunopharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03825-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03825-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03825-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T08:21:14Z","timestamp":1744791674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03825-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3825"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03825-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Health Authority Ethics Committee of the First Affiliated Hospital of Soochow University. All procedures involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Due to the retrospective nature of this study, informed consent was not obtained from patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}